pralatrexate (Compound)

Synonyms:Pralatrexate, 146464-95-1, Folotyn, 10-Propargyl-10-deazaaminopterin, HSDB 7786, PDX, Pralatrexate(Folotyn), CHEBI:71223, (2S)-2-(4-(1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl)benzamido)pentanedioic acid, N-(4-(1-((2,4-Diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-L-glutamic acid, NSC-754230, DTXSID3048578, A8Q8I19Q20, 146464-95-1 (racemic), NSC754230, L-Glutamic acid, N-[4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butyn-1-yl]benzoyl]-, (2S)-2-((4-((1RS)-1-((2,4-Diaminopteridin-6-yl)methyl)but-3-ynyl)benzoyl)amino)pentanedioic acid, NCGC00242596-01, (2S)-2-({4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}amino)pentanedioic acid, (2S)-2-[[4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl]amino]pentanedioic acid, N-{4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}-L-glutamic acid, L-Glutamic acid, N-(4-(1-((2,4-diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-, N -(4-{1-[(2,4-diaminopteridin-6-yl)methyl]but-3-yn-1-yl}benzoyl)-L-glutamic acid, (2S)-2-[[4-[(1RS)-1-[(2,4-diaminopteridin-6-yl)methyl]but-3-ynyl]benzoyl]amino]pentanedioic acid, Folotyn (TN), Pralatrexate [USAN], Pralatrexate [USAN:INN], pralatrexato, pralatrexatum, Pralatrexat, Pralatrexte, UNII-A8Q8I19Q20, PRALATREXATE [MI], PRALATREXATE [INN], PRALATREXATE [JAN], PRALATREXATE [HSDB], PRALATREXATE [VANDF], SCHEMBL21633, PRALATREXATE [MART.], PRALATREXATE [WHO-DD], GTPL6840, Pralatrexate (JAN/USAN/INN), CHEMBL1201746, DTXCID3028504, SCHEMBL15075302, BCPP000101, PRALATREXATE [ORANGE BOOK], EX-A2142, Tox21_112906, BDBM50457437, MFCD00920897, s1497, AKOS015966891, AM84423, CCG-269517, CS-0504, DB06813, NSC 754230, (2S)-2-[[4-[1-[(2,4-diaminopteridin-6-yl)methyl]but-3-ynyl]benzoyl]amino]pentanedioic acid, s11194, 10-Propargyl-10-deazaaminopterin, 95%, NCGC00386226-01, AC-28388, BS-15438, HY-10446, CAS-146464-95-1, P2645, SW220187-1, D05589, AB00443251-02, AB00443251_04, A884505, EN300-26509071, Q637059, SR-01000941578, J-008227, SR-01000941578-1, (2S)-2-({4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]phenyl}formamido)pentanedioic acid, N-(4-(1-((2,4-Diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-L-glutamic acid;Pralatrexate

Pubchem:PUBCHEM:148121

Id:7cb3d767-7784-5aab-ac5a-c3d3e6f17200

Description:nan

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View pralatrexate's neighborhood in the knowledge graph.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for pralatrexate.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with pralatrexate.

Results found

Linked to

	Label	Description
	BRD-A74914197-001-02-9 Substance (Entity type)	A Substance
	DCSTRUCT ID 04117 Collection (Entity type)	DrugPage Collection: (DrugCentralID:04117; PubChem_CID:148121, FILE=drugcentral_drug_04117.json)
	pralatrexate (27a979fa-cbd7-4600-83d5-0e84c6b015e5) Collection (Entity type)	Metadatata for pralatrexate
	pralatrexate positively regulates CCNG1 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	pralatrexate negatively regulates CCNB2 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	pralatrexate in similarity relationship with Gemcitabine Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	pralatrexate negatively regulates GRWD1 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	pralatrexate negatively regulates TPM4 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	pralatrexate negatively regulates CENPF Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	pralatrexate in similarity relationship with methotrexate Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS